StockNews.com Upgrades Antares Pharma (NASDAQ:ATRS) to Buy

Antares Pharma (NASDAQ:ATRS – Get Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a report issued on Tuesday.

Several other equities research analysts have also commented on the stock. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Antares Pharma in a research report on Thursday, February 24th. Zacks Investment Research raised shares of Antares Pharma from a “sell” rating to a “hold” rating in a research note on Monday, March 7th.

Shares of NASDAQ ATRS traded down $0.01 during midday trading on Tuesday, hitting $3.74. The company’s stock had a trading volume of 565,966 shares, compared to its average volume of 771,241. Antares Pharma has a 1 year low of $3.11 and a 1 year high of $4.63. The business’s fifty day simple moving average is $3.77 and its two-hundred day simple moving average is $3.59. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.96 and a quick ratio of 2.76. The firm has a market capitalization of $636.20 million, a price-to-earnings ratio of 13.85 and a beta of 1.52.

Antares Pharma (NASDAQ:ATRS – Get Rating) last released its quarterly earnings data on Thursday, March 3rd. The specialty pharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.01 by $0.01. The company had revenue of $48.73 million for the quarter, compared to analysts’ expectations of $46.25 million. Antares Pharma had a net margin of 25.16% and a return on equity of 12.33%. During the same quarter last year, the company earned $0.03 earnings per share. Analysts anticipate that Antares Pharma will post 0.08 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in ATRS. Barclays PLC increased its position in Antares Pharma by 71.2% in the fourth quarter. Barclays PLC now owns 283,332 shares of the specialty pharmaceutical company’s stock worth $1,011,000 after buying an additional 117,863 shares during the period. BlackRock Inc. boosted its stake in Antares Pharma by 1.2% during the fourth quarter. BlackRock Inc. now owns 12,023,196 shares of the specialty pharmaceutical company’s stock valued at $42,924,000 after buying an additional 147,703 shares in the last quarter. California State Teachers Retirement System boosted its stake in Antares Pharma by 1.8% during the fourth quarter. California State Teachers Retirement System now owns 226,229 shares of the specialty pharmaceutical company’s stock valued at $808,000 after buying an additional 3,976 shares in the last quarter. Parametric Portfolio Associates LLC boosted its stake in Antares Pharma by 15.5% during the fourth quarter. Parametric Portfolio Associates LLC now owns 169,579 shares of the specialty pharmaceutical company’s stock valued at $605,000 after buying an additional 22,814 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY boosted its position in shares of Antares Pharma by 7.8% in the 4th quarter. Metropolitan Life Insurance Co NY now owns 45,536 shares of the specialty pharmaceutical company’s stock valued at $163,000 after purchasing an additional 3,286 shares during the period. Hedge funds and other institutional investors own 48.63% of the company’s stock.

Antares Pharma Company Profile (Get Rating)

Antares Pharma, Inc, a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems.

Read More